Immunic Inc [IMUX] stock is trading at $0.66, up 0.33%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IMUX shares have gain 14.05% over the last week, with a monthly amount drifted -0.82%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immunic Inc [NASDAQ: IMUX] stock has seen the most recent analyst activity on November 07, 2025, when Roth Capital initiated its Buy rating and assigned the stock a price target of $3. Previously, Chardan Capital Markets started tracking the stock with Buy rating on September 29, 2025, and set its price target to $13. On March 25, 2025, William Blair initiated with a Outperform rating. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $10 on November 25, 2024. B. Riley Securities started tracking with a Buy rating for this stock on August 27, 2024, and assigned it a price target of $6. In a note dated October 21, 2022, SVB Leerink downgraded an Mkt Perform rating on this stock but restated the target price of $5.
Immunic Inc [IMUX] stock has fluctuated between $0.51 and $1.39 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Immunic Inc [NASDAQ: IMUX] shares were valued at $0.66 at the most recent close of the market. An investor can expect a potential return of 657.58% based on the average IMUX price forecast.
Analyzing the IMUX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -2.53, Equity is -7.16 and Total Capital is -9.93. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Immunic Inc’s Current Ratio is 1.31. Further, the Quick Ratio stands at 1.31, while the Cash Ratio is 1.17.
Transactions by insiders
Recent insider trading involved Nash Duane, Executive Chairman, that happened on Jun 13 ’25 when 20000.0 shares were purchased. President and COO, Tardio Jason completed a deal on Jun 05 ’25 to buy 12512.0 shares. Meanwhile, CEO and Director Vitt Daniel bought 15000.0 shares on Jun 04 ’25.
